New imaging agent could spot hidden cancers

NCT ID NCT07420036

Not yet recruiting Diagnosis Sponsor: Zhongnan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new radioactive imaging agent called 68Ga-SFB6-ZN01, which is designed to attach to a protein found on many cancer cells. 98 adults with confirmed or suspected cancer will receive a single injection of the agent and then have a PET/CT scan. The goal is to see if the scan can accurately detect and stage tumors, and to check for any side effects. No treatment is given; this is purely a diagnostic study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-SFB6-ZN01 (a radioactive imaging agent injected before a PET/CT scan)
What this could lead to: If successful, this could lead to a more accurate way to detect and stage cancers using PET/CT scans, helping doctors make better treatment decisions.
What could go wrong: This is a very early (Phase 1) study with only 98 participants, so the imaging agent may not work as hoped or may cause unexpected side effects. It is designed to test safety and accuracy, not to treat cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic disease cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

Zhongnan Hospital of Wuhan University

Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.